Advances in opioid pharmacology

Supportive Care in Cancer

Volumn 13, Issue 3, 2005, Pages 153-159

  Gourlay, Geoffrey K ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Metabolism; Opioids; Pharmacology; Receptors

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CODEINE; CYTOCHROME P450; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DIAMORPHINE; FENTANYL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LEVORPHANOL; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXAZONE; NALOXONE; NORMORPHINE; NORPETHIDINE; OPIATE DERIVATIVE; OXYCODONE; PENTAZOCINE; PETHIDINE; RECEPTOR SUBTYPE; SEROTONIN UPTAKE INHIBITOR; SUFENTANIL; UNINDEXED DRUG;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG EFFECT; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RECEPTOR BINDING; GENOTYPE; GRAND MAL SEIZURE; HUMAN; MOLECULAR CLONING; MOLECULAR GENETICS; MYOCLONUS; NAUSEA; NERVOUSNESS; NEUROTOXICITY; NONHUMAN; PAIN ASSESSMENT; PHARMACOGENETICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; RECEPTOR SENSITIVITY; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; TIC; TREMOR; URINE RETENTION; VOMITING;

ANALGESICS, OPIOID; ANIMALS; CODEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; MEPERIDINE; MORPHINE; PAIN MEASUREMENT; PAIN, INTRACTABLE; RECEPTORS, OPIOID; SENSITIVITY AND SPECIFICITY;

EID: 16344367289     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0690-6     Document Type: Review

References (55)

1. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:S3-13
2. Przewlocki R, Przewlocka B (2001) Opioids in chronic pain. Eur J Pharmacol 429:79-91
3. Gilbert PE, Martin WR (1976) Sigma effects of nalorphine in the chronic spinal dog. Drug Alcohol Depend 1:373-376
4. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
5. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495-499
6. Pasternak GW (1980) Multiple opiate receptors: [3H].ethylketocyclazocine receptor binding and ketocyclazocine analgesia. Proc Natl Acad Sci USA 77:3691-3694
7. Pasternak GW (1993) Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16:1-18
8. Knapp RJ, Porreca F, Burks TF, Yamamura HI (1989) Mediation of analgesia by multiple opioid receptors. In: Hill CS, Fields WS (eds) Advances in pain research and therapy. Raven Press, New York, pp 247-289
9. Freye E (1987) New concepts in opioid activity. Opioid agonists, antagonists, and mixed narcotic analgesics: theoretical background and consideration for practical use. Springer, New York, pp 64-66
10. Wolozin BL, Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A 78:6181-6185
11. Traynor JR (1996) The u-opioid receptor. Pain Rev 3:221-248
12. Jiang Q, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI, Porreca F (1991) Differential antagonism of opioid delta antinociception by [D-Ala2, Leu5, Cys6]. enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 257:1069-1075
13. Attali B, Gouarderes C, Mazarguil H, Audigier Y, Cros J (1982) Evidence for multiple "kappa" binding sites by use of opioid peptides in the guinea-pig lumbo-sacral spinal cord. Neuropeptides 3:53-64
14. Chen Y, Mestek A, Liu J, Hurley JA, Yu L (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44:8-12
15. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955
16. Minami M, Toya T, Katao Y, Maekawa K, Nakamura S, Onogi T, Kaneko S, Satoh M (1993) Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett 329:291-295
17. Wei LN, Loh HH (2002) Regulation of opioid receptor expression. Curr Opin Pharmacol 2:69-75
18. Gourlay GK (2002) Clinical pharmacology of the treatment of chronic non-cancer pain. In: Giamberardino MA (ed) Pain 2002 - an updated review (refresher course syllabus). IASP Press, Seattle, pp 381-394
19. Filizola M, Olmea O, Weinstein H (2002) Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. Protein Eng 15:881-885
20. Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700
21. Gaveriaux-Ruff C, Kieffer BL (1999) Opioid receptors: gene structure and function. In: Stein C (ed) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 1-20
22. Gaveriaux-Ruff C, Kieffer BL (2002) Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 36:62-71
23. Trapaidze N, Gomes I, Cvejic S, Bansinath M, Devi LA (2000) Opioid receptor endocytosis and activation of MAP kinase pathway. Brain Res Mol Brain Res 76:220-228
24. Chevlen E (2003) Opioids: a review. Curr Pain Headache Rep 7:15-23
25. Kaufman DL, Keith DE Jr, Anton B, Tian J, Magendzo K, Newman D, Tran TH, Lee DS, Wen C, Xia YR (1995) Characterization of the murine mu opioid receptor gene. J Biol Chem 270:15877-15883
26. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A 94:1544-1549
27. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24:243-252
28. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50, 488H and attenuates morphine withdrawal. EMBO J 17:886-897
29. Simonin F, Slowe S, Becker JA, Matthes HW, Filliol D, Chluba J, Kitchen I, Kieffer BL (2001) Analysis of [3H] bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol 414:189-195
30. Pasternak GW (2001) The pharmacology of mu analgesics: from patients to genes. Neuroscientist 7:220-231
31. Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306
32. Ma MK, Woo MH, McLeod HL (2002) Genetic basis of drug metabolism. Am J Health Syst Pharm 59:2061-2069
33. Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-611
34. Wright AW, Mather LE, Smith MT (2001) Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 69:409-420
35. Roxane Laboratories (2000) Levorphanol (prescribing information). Roxane Laboratories, Columbus, OH
36. Foster DJ, Somogyi AA, Bochner F (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47:403-412
37. Barkin RL, Barkin D (2001) Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J 94:756-770
38. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 68:667-676
39. Smith MT (2000) Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 27:524-528
40. Bartlett SE, Smith MT (1995) The apparent affinity of morphine-3-glucuronide at mul-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand binding. Life Sci 57:609-615
41. Osborne RJ, Joel SP, Slevin ML (1986) Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 292:1548-1549
42. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M (1998) Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27-33
43. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, Reidenberg MM (1983) Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13:180-185
44. Waitman J, McCaffery M (2001) Meperidine - a liability. Am J Nurs 101:57-58
45. Agency for Healthcare Policy and Research (1994) Management of cancer pain, clinical guideline number 9 (AHCPR publication number 94-0592)
46. Boden R, Botting R, Coulson P, Spanswick G (1984) Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice. Br J Pharmacol 82:151-154
47. Ueda H, Fukushima N, Kitao T, Ge M, Takagi H (1986) Low doses of naloxone produce analgesia in the mouse brain by blocking presynaptic autoinhibition of enkephalin release. Neurosci Lett 65:247-252
48. Vaughan CW, Christie MJ (1997) Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol 498 (Pt 2):463-472
49. Cram SM, Shen KF (2001) Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 888:75-82
50. Crain SM, Shen KF (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci U S A 92:10540-10544
51. Wright PM, O'Toole DP, Barron DW (1992) The influence of naloxone infusion on the action of intrathecal diamorphine: low-dose naloxone and neuroendocrine responses. Acta Anaesthesiol Scand 36:230-233
52. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER (1999) Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 90:1007-1011
53. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R (1997) Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87:1075-1081
54. Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB (2002) The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 96:73-79
55. Mehlisch DR (2003) The combination of low dose of naloxone and morphine in patient-controlled (PCA) does not decrease opioid requirements in the postoperative period. Pain 101:209-211